fr   en

Browse by date
Or search by keyword
Date: 2010-08-03
Biotech partner: Telormedix (Switzerland) Swiss Tropical and Public Health Institute (Swiss TPH - Switzerland)
Type of agreement: * R&D
* other
Compound: TMX-201 This second generation TLR7 molecule is intended to act as an activator of the innate immune system and enhance the process of immunisation.
Disease area: Malaria and Buruli Ulcer
Development phase: pilot study
Nature of the agreement: Telormedix, and the Swiss Tropical and Public Health Institute (Swiss TPH) have decided to collaborate on a pilot study using Telormedix’s adjuvant, TMX-201, in connection with immunization for Malaria and Buruli Ulcer.
The study is focused on the testing of TMX-201 as a novel adjuvant in comparison with a standard adjuvant in a vaccination trial with two prototype antigens, one from Plasmodium falciparum (Malaria) and one from Mycobacterium ulcerans (Buruli Ulcer). This pilot study will be performed under the direction of Prof. Dr. Gerd Pluschke, Head of the Department of Parasitology and Infection Biology at the Swiss TPH.

Go back to previous page